171 related articles for article (PubMed ID: 24467642)
21. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
Rimsky L; Vingerhoets J; Van Eygen V; Eron J; Clotet B; Hoogstoel A; Boven K; Picchio G
J Acquir Immune Defic Syndr; 2012 Jan; 59(1):39-46. PubMed ID: 22067667
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents.
Jantarabenjakul W; Anugulruengkitt S; Kasipong N; Thammajaruk N; Sophonphan J; Bunupuradah T; Cressey TR; Colbers A; Burger DM; Phongsamart W; Puthanakit T; Pancharoen C;
Antivir Ther; 2018; 23(3):259-265. PubMed ID: 28994660
[TBL] [Abstract][Full Text] [Related]
23. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
Vingerhoets J; Rimsky L; Van Eygen V; Nijs S; Vanveggel S; Boven K; Picchio G
Antivir Ther; 2013; 18(2):253-6. PubMed ID: 22951490
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.
Wilkin A; Pozniak AL; Morales-Ramirez J; Lupo SH; Santoscoy M; Grinsztejn B; Ruxrungtham K; Rimsky LT; Vanveggel S; Boven K;
AIDS Res Hum Retroviruses; 2012 May; 28(5):437-46. PubMed ID: 21902621
[TBL] [Abstract][Full Text] [Related]
25. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
26. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
[TBL] [Abstract][Full Text] [Related]
27. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
[TBL] [Abstract][Full Text] [Related]
28. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
Cooper DA; Heera J; Ive P; Botes M; Dejesus E; Burnside R; Clumeck N; Walmsley S; Lazzarin A; Mukwaya G; Saag M; van Der Ryst E
AIDS; 2014 Mar; 28(5):717-25. PubMed ID: 24983542
[TBL] [Abstract][Full Text] [Related]
30. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
[TBL] [Abstract][Full Text] [Related]
31. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
Lennox JL; Dejesus E; Berger DS; Lazzarin A; Pollard RB; Ramalho Madruga JV; Zhao J; Wan H; Gilbert CL; Teppler H; Rodgers AJ; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Sklar P;
J Acquir Immune Defic Syndr; 2010 Sep; 55(1):39-48. PubMed ID: 20404738
[TBL] [Abstract][Full Text] [Related]
32. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE
J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537
[TBL] [Abstract][Full Text] [Related]
33. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Penazzato M; Giaquinto C
Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
[TBL] [Abstract][Full Text] [Related]
34. Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.
Ripamonti D; Bombana E; Rizzi M
Expert Rev Anti Infect Ther; 2014 Jan; 12(1):13-29. PubMed ID: 24308712
[TBL] [Abstract][Full Text] [Related]
35. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
Schafer JJ; Short WR
Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
[TBL] [Abstract][Full Text] [Related]
36. Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
Porter DP; Kulkarni R; Garner W; Miller MD; White KL
Antivir Ther; 2017; 22(6):495-502. PubMed ID: 28091393
[TBL] [Abstract][Full Text] [Related]
37. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
38. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.
Li SL; Xu P; Zhang L; Sun GX; Lu ZJ
HIV Clin Trials; 2014; 15(6):261-8. PubMed ID: 25433665
[TBL] [Abstract][Full Text] [Related]
40. Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances.
Lapadula G; Bernasconi DP; Bai F; Focà E; Di Biagio A; Bonora S; Castelli F; Squillace N; Bandera A; Monforte AD; Migliorino GM; Gori A;
AIDS; 2020 Jan; 34(1):53-61. PubMed ID: 31567160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]